Delpharm is a worldwide leader in contract manufacturing and development of medicines with :
- 19 plants in France, Italy, Canada, Poland and The Netherlands
- Over 1,1 billion euros turnover
- Over 6,500 people
- 6,500 people working in the company
- Most dosage forms produced
For over 35 years, Delpharm has grown by progressively acquiring production plants, notably from major pharmaceutical laboratories. Today, Delpharm operates 18 industrial sites and 3 development centers located in France, Italy, Canada, the Netherlands, and Poland, producing over one billion boxes of medicines per year and contributing to the development of numerous projects.
As multi-specialists, Delpharm is able to supply the majority of pharmaceutical forms available on the market, such as tablets and capsules, bottles and injectable ampoules, prefilled syringes, freeze-drying, suspensions, solutions, ointments and soft gel capsules.
Delpharm also offers full development services for a wide range of pharmaceutical forms, chemical entities and innovative combinations, including the production of phase 1 to 3 clinical batches for solid, semi-solid, liquid and injectable forms.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
What industry is Delpharm in?
Delpharm operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Delpharm based?
Delpharm is headquartered in Boulogne-Billancourt, France.
Find investors for your startup like Delpharm
Gritt sends AI-personalised outreach to each investor — from your Gmail
